ProMIS Neurosciences (PMN) Institutional Ownership → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free PMN Stock Alerts $1.98 +0.03 (+1.54%) (As of 04/26/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for ProMIS Neurosciences (NASDAQ:PMN)CurrentInstitutional OwnershipPercentage50.13%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$526.68KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$9.65K Get PMN Insider Trade Alerts Want to know when executives and insiders are buying or selling ProMIS Neurosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> ProMIS Neurosciences Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/7/2024Ieq Capital LLC30,799$35K0.0%-21.4%0.163% 11/15/2023Affinity Asset Advisors LLC265,958$527K0.1%N/A3.100% 11/15/2022Northeast Financial Consultants Inc100,000$613K0.0%N/A1.166% 11/4/2022Ieq Capital LLC39,191$240K0.0%N/A0.457% (Data available from 1/1/2016 forward) PMN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of PMN shares? During the previous two years, the following institutional investors and hedge funds held shares of ProMIS Neurosciences shares: Northeast Financial Consultants Inc ($613K), and Affinity Asset Advisors LLC ($527K), Ieq Capital LLC ($35K).Learn more on PMN's institutional investors. What percentage of ProMIS Neurosciences stock is owned by institutional investors? 50.13% of ProMIS Neurosciences stock is owned by institutional investors. Learn more on PMN's institutional investor holdings. Which institutional investors have been buying ProMIS Neurosciences stock? The following institutional investors have purchased ProMIS Neurosciences stock in the last 24 months: Affinity Asset Advisors LLC ($265.96K), Northeast Financial Consultants Inc ($100K), and Ieq Capital LLC ($39.19K). How much institutional buying is happening at ProMIS Neurosciences? Institutional investors have bought a total of 405,149 shares in the last 24 months. This purchase volume represents approximately $1.38M in transactions. Which ProMIS Neurosciences major shareholders have been selling company stock? The following institutional investors have sold ProMIS Neurosciences stock in the last 24 months: Ieq Capital LLC ($8.39K). How much institutional selling is happening at ProMIS Neurosciences? Institutional investors have sold a total of 8,392 shares in the last 24 months. This volume of shares sold represents approximately $9.65K in transactions. Related Companies: Cara Therapeutics Major Shareholders Marker Therapeutics Major Shareholders Ocuphire Pharma Major Shareholders Unicycive Therapeutics Major Shareholders BriaCell Therapeutics Major Shareholders Xilio Therapeutics Major Shareholders Bolt Biotherapeutics Major Shareholders NextCure Major Shareholders Apollomics Major Shareholders Fortress Biotech Major Shareholders This page (NASDAQ:PMN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.